AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 6220729 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg and hyoscine 0.4 mg
Number of subjects: 0
Study 6220729 — intervention group
Group type: COMPARATOR
Intervention: Papaveretum 20 mg and hyoscine 0.4 mg
Number of subjects: 0
Study 6220729 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine-hyoscine
Number of subjects: 0
Study 6220729 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 0.3 mg and papaveretum 20 mg
Number of subjects: 0
Study 31867643 — intervention group
Group type: EXPERIMENTAL
Intervention: Very Low Nicotine Content (VLNC) cigarettes
Number of subjects: 68
Study 31867643 — intervention group
Group type: COMPARATOR
Intervention: Reducing number of cigarettes per day (CPD)
Number of subjects: 68
Study 30179958 — intervention group
Group type: EXPERIMENTAL
Intervention: Robot-assisted surgery
Number of subjects: 130
Study 30179958 — intervention group
Group type: COMPARATOR
Intervention: Hand-rasping technique
Number of subjects: 130
Study 26418044 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based auditory training program (12 weeks, 5 days/week)
Number of subjects: 39
Study 26418044 — intervention group
Group type: COMPARATOR
Intervention: Standard treatment for APD (control group)
Number of subjects: 39
Study 25085020 — intervention group
Group type: EXPERIMENTAL
Intervention: Fennel (30 mg) soft capsule every 4 hours, 3 days before menstruation until the 5th day for 3 months
Number of subjects: 80
Study 25085020 — intervention group
Group type: COMPARATOR
Intervention: Control group (no medication)
Number of subjects: 80
Study 22606852 — intervention group
Group type: EXPERIMENTAL
Intervention: Botulinum toxin injections
Number of subjects: 30
Study 22606852 — intervention group
Group type: EXPERIMENTAL
Intervention: Fascial Manipulation
Number of subjects: 30
Study 19237093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg (b.i.d.), amoxicillin 1 g (b.i.d.), doxycycline 100 mg (b.i.d.)
Number of subjects: 115
Study 19237093 — intervention group
Group type: EXPERIMENTAL
Intervention: Ranitidine bismuth citrate 400 mg (b.i.d.), amoxicillin 1 g (b.i.d.), tetracycline 500 mg (q.i.d.)
Number of subjects: 115
Study 17227905 — intervention group
Group type: EXPERIMENTAL
Intervention: Sunitinib
Number of subjects: 0
Study 17227905 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 15356061 — intervention group
Group type: EXPERIMENTAL
Intervention: Repaglinide (1 mg)
Number of subjects: 0
Study 15356061 — intervention group
Group type: EXPERIMENTAL
Intervention: Glipizide (5 mg)
Number of subjects: 0
Study 11265936 — intervention group
Group type: EXPERIMENTAL
Intervention: Telemedicine GPs (n = 126)
Number of subjects: 426
Study 11265936 — intervention group
Group type: COMPARATOR
Intervention: Control GPs (n = 300)
Number of subjects: 426
Study 9555920 — intervention group
Group type: EXPERIMENTAL
Intervention: Students who were given a rule for diagnosis
Number of subjects: 120
Study 9555920 — intervention group
Group type: EXPERIMENTAL
Intervention: Students in the PT group
Number of subjects: 120
Study 9555920 — intervention group
Group type: COMPARATOR
Intervention: Students who were not given a rule
Number of subjects: 120
Study 8087788 — intervention group
Group type: EXPERIMENTAL
Intervention: Androgen withdrawal, androgen blockade, or combination therapy (first-line treatment modalities)
Number of subjects: 0
Study 8087788 — intervention group
Group type: COMPARATOR
Intervention: Not specified
Number of subjects: 0
Study 2659995 — intervention group
Group type: EXPERIMENTAL
Intervention: Silver sulfadiazine cream containing epidermal growth factor (10 micrograms per milliliter)
Number of subjects: 12
Study 2659995 — intervention group
Group type: COMPARATOR
Intervention: Silver sulfadiazine cream
Number of subjects: 12
Study 31290550 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cessation treatment for SM smokers
Number of subjects: 2637
Study 31290550 — intervention group
Group type: EXPERIMENTAL
Intervention: Web-based cessation treatment for bisexual smokers
Number of subjects: 2637
Study 31228618 — intervention group
Group type: EXPERIMENTAL
Intervention: Sublingual immunotherapy (SLIT) plus pharmacotherapy
Number of subjects: 102
Study 31228618 — intervention group
Group type: COMPARATOR
Intervention: Standard pharmacotherapy alone
Number of subjects: 102
Study 28378301 — intervention group
Group type: EXPERIMENTAL
Intervention: Enhanced intervention (integrated intervention incorporating social determinants of health)
Number of subjects: 54
Study 28378301 — intervention group
Group type: COMPARATOR
Intervention: Basic intervention (integrated intervention alone)
Number of subjects: 54
Study 26074287 — intervention group
Group type: EXPERIMENTAL
Intervention: wound infiltration with 15 ml of ropivacaine 10%
Number of subjects: 400
Study 26074287 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 400
Study 23838478 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus paracasei F19 (LF19)
Number of subjects: 179
Study 23838478 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 179
Study 21857268 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiorifice catheter (2.5 cm)
Number of subjects: 153
Study 21857268 — intervention group
Group type: EXPERIMENTAL
Intervention: Multiorifice catheter (5 cm)
Number of subjects: 153
Study 21857268 — intervention group
Group type: COMPARATOR
Intervention: End-hole catheter (0.5 cm)
Number of subjects: 153
Study 18930987 — intervention group
Group type: EXPERIMENTAL
Intervention: Infliximab (3 mg/kg) administered intravenously at weeks 0, 2, 6, and every 8 weeks thereafter to week 54
Number of subjects: 26
Study 18930987 — intervention group
Group type: COMPARATOR
Intervention: Control group (placebo) not explicitly mentioned in the outcomes
Number of subjects: 26
Study 16757921 — intervention group
Group type: EXPERIMENTAL
Intervention: Symptomatic PAR
Number of subjects: 232
Study 16757921 — intervention group
Group type: EXPERIMENTAL
Intervention: PAR
Number of subjects: 232
Study 16757921 — intervention group
Group type: EXPERIMENTAL
Intervention: PAR (asymptomatic)
Number of subjects: 232
Study 16757921 — intervention group
Group type: EXPERIMENTAL
Intervention: PAR (symptomatic)
Number of subjects: 232
Study 16757921 — intervention group
Group type: COMPARATOR
Intervention: Control
Number of subjects: 232
Study 16757921 — intervention group
Group type: EXPERIMENTAL
Intervention: PO
Number of subjects: 232
Study 16757921 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal allergy
Number of subjects: 232
Study 14568836 — intervention group
Group type: EXPERIMENTAL
Intervention: Single treatment with topical 20% 5‐aminolevulinic acid for 3 hours or 14 to 18 hours followed by LP PDL irradiation at 595 nm
Number of subjects: 41
Study 14568836 — intervention group
Group type: COMPARATOR
Intervention: LP PDL irradiation alone (control group)
Number of subjects: 41
Study 10969448 — intervention group
Group type: EXPERIMENTAL
Intervention: Miacalcic (100 IU dose, intramuscularly)
Number of subjects: 10
Study 10969448 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcinin (100 IU dose, intramuscularly)
Number of subjects: 10
Study 8784757 — intervention group
Group type: EXPERIMENTAL
Intervention: NaHCO3 (2 mEq.min‐1)
Number of subjects: 7
Study 8784757 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 1370511 — intervention group
Group type: EXPERIMENTAL
Intervention: Preseasonal alum-precipitated aqueous extracts of ragweed
Number of subjects: 27
Study 1370511 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 27
Study 2578716 — intervention group
Group type: EXPERIMENTAL
Intervention: Trioxsalen bath PUVA
Number of subjects: 93
Study 2578716 — intervention group
Group type: COMPARATOR
Intervention: Oral methoxsalen PUVA
Number of subjects: 93
Study 30545775 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral lenses worn for 5 hours (Group 1)
Number of subjects: 20
Study 30545775 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral lenses worn for 20 minutes (Group 2)
Number of subjects: 20
Study 30545775 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral lenses worn for 5 hours (Group 2)
Number of subjects: 20
Study 30545775 — intervention group
Group type: EXPERIMENTAL
Intervention: Scleral lenses worn for 5 hours and 20 minutes
Number of subjects: 20
Study 29330660 — intervention group
Group type: EXPERIMENTAL
Intervention: Theobromine (500 mg/day)
Number of subjects: 44
Study 29330660 — intervention group
Group type: COMPARATOR
Intervention: High-fat mixed meal
Number of subjects: 44
Study 28383633 — intervention group
Group type: COMPARATOR
Intervention: Capecitabine (1250 mg/m2 for patients <70 years; 1000 mg/m2 for patients ≥70 years, twice daily on days 1-14)
Number of subjects: 161
Study 28383633 — intervention group
Group type: EXPERIMENTAL
Intervention: S-1 (30 mg/m2 orally twice daily on days 1-14)
Number of subjects: 161
Study 26358345 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal triamcinolone acetonide 220 μg once daily for 28 days
Number of subjects: 149
Study 22878130 — intervention group
Group type: EXPERIMENTAL
Intervention: High-output VNS stimulation
Number of subjects: 41
Study 22878130 — intervention group
Group type: COMPARATOR
Intervention: Low-output (active control) VNS stimulation
Number of subjects: 41
Study 22878130 — intervention group
Group type: EXPERIMENTAL
Intervention: High-output VNS stimulation (open-label phase)
Number of subjects: 41
Study 21884606 — intervention group
Group type: EXPERIMENTAL
Intervention: Low dose vitamin A supplementation (VAS)
Number of subjects: 8626
Study 21884606 — intervention group
Group type: COMPARATOR
Intervention: Recommended dose vitamin A supplementation (VAS)
Number of subjects: 8626
Study 19994681 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut implantation at acupoint (Shenshu, Zigong, Sanyinjiao)
Number of subjects: 60
Study 19994681 — intervention group
Group type: COMPARATOR
Intervention: Western medicine group (oral administration of Diethylstilbestrol tablet)
Number of subjects: 60
Study 19994681 — intervention group
Group type: EXPERIMENTAL
Intervention: Catgut implantation group
Number of subjects: 60
Study 19994681 — intervention group
Group type: COMPARATOR
Intervention: Western medicine group
Number of subjects: 60
Study 17900050 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT treatment (bitemporal ECT 3 times a week)
Number of subjects: 20
Study 17900050 — intervention group
Group type: COMPARATOR
Intervention: Imipramine or desipramine (150-250 mg/day)
Number of subjects: 20
Study 17900050 — intervention group
Group type: EXPERIMENTAL
Intervention: ECT treatment
Number of subjects: 20
Study 15573541 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic availability of task-related information
Number of subjects: 48
Study 15573541 — intervention group
Group type: COMPARATOR
Intervention: Availability of task-related information upon request
Number of subjects: 48
Study 15573541 — intervention group
Group type: COMPARATOR
Intervention: No availability of task-related information
Number of subjects: 48
Study 11951995 — intervention group
Group type: EXPERIMENTAL
Intervention: New formula (<0.1 mg Fe 100 ml(‐1))
Number of subjects: 149
Study 11951995 — intervention group
Group type: COMPARATOR
Intervention: Standard formula (0.5 mg Fe 100 ml(‐1))
Number of subjects: 149
Study 11951995 — intervention group
Group type: COMPARATOR
Intervention: Breastfed reference group
Number of subjects: 149
Study 9849711 — intervention group
Group type: EXPERIMENTAL
Intervention: Extra-amniotic balloon with intracervical PGE2 (0.5 mg x 2)
Number of subjects: 68
Study 9849711 — intervention group
Group type: COMPARATOR
Intervention: Extra-ovular Foley catheter with intrauterine PGF2alpha (1 mg/h x 6)
Number of subjects: 68
Study 7746297 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine 250 mg b.i.d. for 4 weeks
Number of subjects: 118
Study 7746297 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole 200 mg once-daily for 4 weeks
Number of subjects: 118
Study 7746297 — intervention group
Group type: EXPERIMENTAL
Intervention: Terbinafine
Number of subjects: 118
Study 7746297 — intervention group
Group type: COMPARATOR
Intervention: Ketoconazole
Number of subjects: 118
Study 2563963 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonenteric coated pancreatic enzyme supplement without ranitidine
Number of subjects: 12
Study 2563963 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonenteric coated pancreatic enzyme supplement with ranitidine
Number of subjects: 12
Study 2563963 — intervention group
Group type: EXPERIMENTAL
Intervention: Enteric coated pancreatic enzyme supplements
Number of subjects: 12
Study 2563963 — intervention group
Group type: COMPARATOR
Intervention: Control group (baseline studies)
Number of subjects: 12
Study 31913578 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension defined by 140/90 mm Hg threshold
Number of subjects: 4515
Study 31913578 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension defined by 130/80 mm Hg threshold
Number of subjects: 4515
Study 30735435 — intervention group
Group type: EXPERIMENTAL
Intervention: Chemotherapy with pembrolizumab
Number of subjects: 0
Study 30735435 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy alone (Control)
Number of subjects: 0
Study 28169880 — intervention group
Group type: EXPERIMENTAL
Intervention: Antihypertensive treatment
Number of subjects: 4071
Study 28169880 — intervention group
Group type: COMPARATOR
Intervention: Control (discontinue all antihypertensive medications)
Number of subjects: 4071
Study 25459101 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose endotoxin
Number of subjects: 63
Study 25459101 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study 23172001 — intervention group
Group type: EXPERIMENTAL
Intervention: Problem-solving bibliotherapy intervention (PSBI)
Number of subjects: 124
Study 23172001 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (TAU)
Number of subjects: 124
Study 20179652 — intervention group
Group type: EXPERIMENTAL
Intervention: Core stability tests (flexion, extension, right and left lateral)
Number of subjects: 28
Study 20179652 — intervention group
Group type: EXPERIMENTAL
Intervention: T-run (TR)
Number of subjects: 28
Study 20179652 — intervention group
Group type: EXPERIMENTAL
Intervention: Functional movement screen (FMS) tests (deep squat, trunk-stability push-up, right and left hurdle step, in-line lunge, shoulder mobility, active straight leg raise, rotary stability)
Number of subjects: 28
Study 20179652 — intervention group
Group type: EXPERIMENTAL
Intervention: Single leg squat (SLS)
Number of subjects: 28
Study 19907103 — intervention group
Group type: EXPERIMENTAL
Intervention: Olmesartan medoxomil 20 mg/day for 12 months
Number of subjects: 70
Study 19907103 — intervention group
Group type: COMPARATOR
Intervention: Amlodipine besilate 5 mg/day for 12 months
Number of subjects: 70
Study 16491550 — intervention group
Group type: EXPERIMENTAL
Intervention: Atorvastatin 80 mg/day
Number of subjects: 8888
Study 16491550 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20-40 mg/day
Number of subjects: 8888
Study 15519712 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 696
Study 15519712 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 696
Study 10644808 — intervention group
Group type: EXPERIMENTAL
Intervention: White cell-reduced irradiated blood (Group 1)
Number of subjects: 14
Study 10644808 — intervention group
Group type: COMPARATOR
Intervention: Non-white-cell reduced irradiated blood (Group 2)
Number of subjects: 14
Study 10644808 — intervention group
Group type: COMPARATOR
Intervention: Comparison with healthy term infants (cord blood from 11 infants)
Number of subjects: 14
Study 9062436 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administration of questionnaires
Number of subjects: 68
Study 8383388 — intervention group
Group type: EXPERIMENTAL
Intervention: Inactivated hepatitis A vaccine (25 units, intramuscular)
Number of subjects: 0
Study 6919664 — intervention group
Group type: EXPERIMENTAL
Intervention: One-to-one BSE instruction (experimental group)
Number of subjects: 180
Study 6919664 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 180
Study 30770758 — intervention group
Group type: EXPERIMENTAL
Intervention: L-theanine supplementation (150 mg for 6 weeks)
Number of subjects: 20
Study 30770758 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 28205203 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 60
Study 28205203 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerobic Training (AT)
Number of subjects: 60
Study 28205203 — intervention group
Group type: EXPERIMENTAL
Intervention: Combination Training (CT)
Number of subjects: 60
Study 28205203 — intervention group
Group type: COMPARATOR
Intervention: Control (CON)
Number of subjects: 60
Study 25847306 — intervention group
Group type: EXPERIMENTAL
Intervention: Cumulative risk score of 15 or more
Number of subjects: 21575
Study 25847306 — intervention group
Group type: EXPERIMENTAL
Intervention: Derivation group
Number of subjects: 21575
Study 25847306 — intervention group
Group type: EXPERIMENTAL
Intervention: Validation group
Number of subjects: 21575
Study 23945460 — intervention group
Group type: EXPERIMENTAL
Intervention: Life Goals Collaborative Care (LGCC)
Number of subjects: 118
Study 23945460 — intervention group
Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 118
Study 21059187 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent intervention
Number of subjects: 2937
Study 21059187 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined parent-student intervention
Number of subjects: 2937
Study 21059187 — intervention group
Group type: COMPARATOR
Intervention: Student intervention
Number of subjects: 2937
Study 21059187 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 2937
Study 19296980 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive behavioral change intervention (226 participants)
Number of subjects: 338
Study 19296980 — intervention group
Group type: COMPARATOR
Intervention: Structured education program (112 participants)
Number of subjects: 338
Study 17534246 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct stenting
Number of subjects: 103
Study 17534246 — intervention group
Group type: COMPARATOR
Intervention: Pre-dilated stenting
Number of subjects: 103
Study 16939738 — intervention group
Group type: EXPERIMENTAL
Intervention: Volume-controlled (VC) ventilation
Number of subjects: 0
Study 16939738 — intervention group
Group type: COMPARATOR
Intervention: Time-cycled pressure-limited (TCPL) ventilation
Number of subjects: 0
Study 12904193 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 10-min group (3 microg x kg‐1 of clonidine administered for 10 min immediately after the spinal block)
Number of subjects: 78
Study 12904193 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 60-min group (3 microg x kg‐1 of clonidine administered for 10 min, 50 min after the spinal block)
Number of subjects: 78
Study 12904193 — intervention group
Group type: COMPARATOR
Intervention: Control group (normal saline)
Number of subjects: 78
Study 12904193 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine 10-min group
Number of subjects: 78
Study 12904193 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 78
Study 10498132 — intervention group
Group type: EXPERIMENTAL
Intervention: High-pressure postdilation (> or = 13 atm, group B)
Number of subjects: 181
Study 10498132 — intervention group
Group type: COMPARATOR
Intervention: Low-pressure implantation (6 to 12 atm, group A)
Number of subjects: 181
Study 10498132 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 181
Study 10498132 — intervention group
Group type: EXPERIMENTAL
Intervention: Angiographic follow-up
Number of subjects: 181
Study 7854171 — intervention group
Group type: EXPERIMENTAL
Intervention: Enalapril (20 to 40 mg/d)
Number of subjects: 16
Study 7854171 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study 1791391 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus 600 mg per day for 30 days
Number of subjects: 65
Study 1791391 — intervention group
Group type: EXPERIMENTAL
Intervention: Phyllanthus amarus 1,200 mg per day for 30 days
Number of subjects: 65
Study 1791391 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 6801079 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg metoclopramide
Number of subjects: 11
Study 6801079 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11
Study 6801079 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium infusion
Number of subjects: 11
Study 6801079 — intervention group
Group type: COMPARATOR
Intervention: Saline infusion
Number of subjects: 11
Study 30675745 — intervention group
Group type: EXPERIMENTAL
Intervention: Flaminal R Forte
Number of subjects: 89
Study 30675745 — intervention group
Group type: COMPARATOR
Intervention: Flamazine R
Number of subjects: 89
Study 28129661 — intervention group
Group type: EXPERIMENTAL
Intervention: Segmental re-examination of the proximal colon
Number of subjects: 360
Study 28129661 — intervention group
Group type: COMPARATOR
Intervention: Extended withdrawal time (EWT)
Number of subjects: 360
Study 26407698 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 % silver nitrate (AgNO3) solution followed by 5 % sodium fluoride (NaF) varnish
Number of subjects: 1070
Study 26407698 — intervention group
Group type: COMPARATOR
Intervention: 38 % silver diamine fluoride (SDF) solution
Number of subjects: 1070
Study 23868537 — intervention group
Group type: EXPERIMENTAL
Intervention: Iron rich snacks cooked in iron pots
Number of subjects: 27
Study 22214115 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia-based educational interventions with authenticity strategy
Number of subjects: 53
Study 22214115 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimedia-based educational interventions with motivation strategy
Number of subjects: 53
Study 22214115 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 53
Study 19486469 — intervention group
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a (40 KDa) 180 microg/week plus ribavirin 1000/1200 mg/day for 48 weeks
Number of subjects: 569
Study 16935609 — intervention group
Group type: COMPARATOR
Intervention: 25-gauge vitrectomy
Number of subjects: 67
Study 16935609 — intervention group
Group type: EXPERIMENTAL
Intervention: 20-gauge vitrectomy
Number of subjects: 67
Study 12969097 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine (E) 70 micro g kg‐1
Number of subjects: 33
Study 12969097 — intervention group
Group type: EXPERIMENTAL
Intervention: Esmolol (Es) 500 micro g kg‐1
Number of subjects: 33
Study 12969097 — intervention group
Group type: COMPARATOR
Intervention: Placebo (P)
Number of subjects: 33